Skip to main content
. 2017 Aug 25;18(9):1852. doi: 10.3390/ijms18091852

Table 1.

Studies involving the use of mesenchymal stem cells-conditioned medium (MSC-CM).

Pathologies Donor cells References
Lung injury BMMSCs [55]
Myocardial infarction ADSCs [56]
Cerebral injury/ischemia/stroke BMMSCs [57]
Spinal cord injury BMMSCs [58]
Prevention of muscular degeneration ADSCs [59]
Acute and chronic hind limb ischemia ADSCs [60]
Skin wound healing ADSCs [61]
Colitis Amniotic fluid [62]
Acute liver injury/failure Amniotic fluid [63]
Alzheimer’s disease DPSCs [64]
Bone defects BMMSCs [65]
Osteoarthritis WJMSCs [66]
Corneal epithelial wound healing hUCESCs [49]
Uveitis hUCESCs [50]
Alopecia ADSCs [67]
Liver fibrosis UCPVCs [68]
Parkinson’s disease WJMSCs [69]
Multiple esclerosis PDLSCs [70]
Regeneration of atrophied muscles UCPVCs [71]
Cancer hUCESCs [23]

BMMSCs: Bone marrow-derived mesenchymal stem cells; ADSCs: Adipose-derived stem cells; DPSC: Dental pulp stem cells; WJMSCs: Umbilical cord Wharton's Jelly mesenchymal stem cells; hUCESCs: Human uterine cervical stem cells; UCPVCs: Umbilical cord perivascular cells; PDLSCs: Periodontal ligament stem cells.